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Abstract
Numerous studies have found that depression is a strong independent risk factor for incident coronary
heart disease (CHD), with increasing risk among those with higher levels of depressive symptoms.
We examined the association between measures of inflammation (C-reactive protein, interleukin-6,
soluble intracellular adhesion molecule-1), depressive symptoms, and CHD incidence among 1,794
participants of the population-based Canadian Nova Scotia Health Survey. There were 152 (8.5%)
incident CHD events (141 nonfatal, 11 fatal) during the 15,514 person-years of observation
(incidence rate=9.8 events/1000 person-years). Depression and inflammation were correlated at
baseline and each significantly predicted CHD in separate models. When both risk factors were in
the same model, each remained significant. The association between depressed group by the Center
for Epidemiological Studies—Depression scale (score of 10+ vs. 0–9) and CHD incidence (HR=1.60,
95% CI = 1.12–2.27) was not reduced by the addition of inflammatory markers to the model
(HR=1.59, 95% CI = 1.12–2.26). Findings were similar after adjustment for aspirin, lipid-lowering
medication or anti-depressant use, and the association did not vary by sex, smoking status, age,
obesity, cardiovascular medication use or antidepressant use. In conclusion, increased inflammation
explains only a very small proportion of the association between depression and incident CHD.
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Three pieces of evidence from a number of studies have led researchers to hypothesize that
inflammation is a biologically plausible mechanism to at least partially explain how depressive
symptoms increase the risk of CHD incidence: 1) depressive symptoms independently predict
incident CHD1–3; 2) inflammatory biomarkers predict incident CHD4–6 and; 3) cross-
sectional studies indicate that there is a statistically significant correlation between depressive
symptoms and inflammatory markers7, 8. Thus, it has been widely speculated that
proinflammatory processes are the link between depressive symptoms and CHD8–12. The
replication of all three of these findings in a single study is required to properly test if
inflammation is implicated as a mechanism. Only one recent study13 has examined these
findings within a single sample, but it was limited to women with suspected coronary ischemia.
Therefore, we investigated whether inflammation accounts for some of the excess CHD risk
conferred by depression in a large population-based sample of initially healthy Nova Scotians
who were prospectively followed over 10 years for CHD occurrence.
Methods
The NSHS95 study14 is a population-based survey implemented by Heart Health Nova Scotia
in partnership with the Nova Scotia Department of Health to estimate the distributions of
selected health indicators and preventive practices of Nova Scotians. The sample (n=3,227)
was drawn based on a probability sample designed by Statistics Canada, the national statistical
agency and census bureau, to be representative of the Nova Scotian population by age, gender
and geographic location. The targeted population consisted of all non-institutionalized Nova
Scotians age 18 and above whose names were listed in the Medical Service Insurance register
(MSI), the government-sponsored, universal health insurance plan. The overall recruitment
percentage (72%) is comparable to other large health surveys, and weights applied from
propensity analyses to test for response bias revealed no meaningful biases15. Pregnant women
were excluded from the survey, as their CHD risk factor levels were not considered stable.
Exclusion criteria for the present analysis included participants who had a pre-existing medical
diagnosis of cardiovascular disease or who did not attend the clinic session. Participants whose
high sensitivity C-reactive protein (hs-CRP) levels were above 10 mg/L were also excluded as
acute or chronic inflammatory infections (by proxy) might obfuscate the role of inflammatory
markers in the association between depression and CHD16.
Details of data collection are presented in Rowan et al,17 where results of depression to 4-year
CHD outcome are shown, but without any inflammatory marker information. Briefly, from
March through November of 1995, participants were asked to attend a health care clinic for
assessment of height and weight by a nurse (twice, average used to calculate body mass index
[BMI]). Nurses also measured resting systolic (SBP) and diastolic (DBP) blood pressures four
times using a manual random zero sphygmomanometer; we averaged two readings from home
and two readings from the clinic session, which was usually one week later.
Participants were asked to fast for 12 hours before giving blood samples. Those who reported
fasting for at least 8 hours were considered to have valid fasting blood draws. After
centrifugation, one aliquot was immediately shipped on ice for centralized lipid determination.
Total cholesterol and high-density cholesterol were assayed from plasma samples by the Lipid
Research Laboratory, University of Toronto18. Low-density lipoprotein (LDL) cholesterol was
calculated using the Friedewald formula19. Remaining plasma samples were frozen and stored
at −80 degrees Celsius, and subsequently assayed for inflammatory markers.
On the home visit, the nurse requested all prescription and non-prescription medications/
supplements. The nurse recorded the generic drug name, the brand name, the number of pills
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in the bottle, the date of prescription, and the dosing instructions. The nurse then asked the
participant to report which medications were taken regularly, and on what schedule. Drugs
were coded using the World Health Organization Nordic Anatomical, Therapeutic and
Chemical (ATC) code classification valid in 199520. Data on aspirin, antihypertensive, lipid-
lowering, and antidepressant medication were employed.
Participants provided written consent, allowing linkage to their health care utilization data, and
for the storage and future use of blood assays. IRB approval was originally obtained for the
baseline protocol, and was subsequently obtained for inflammatory marker testing at both
Dalhousie University in Canada and Columbia University.
Depressive symptoms were measured using the Centers for Epidemiological Studies-
Depression (CES-D) scale21, a 20-item self-report instrument that was designed for use in
epidemiological studies as a measure of current level of depressive symptoms. This scale was
treated as a continuous measure, and the Cronbach alpha in this sample was .88.
Three inflammatory markers were measured for this analysis, high sensitivity hs-CRP,
interleukin-6 (IL-6) and soluble intercellular adhesion molecule-1 (sICAM-1). Hs-CRP levels
were measured in plasma samples using a latex-enhanced immunonephelometry assay
(Cardiophase BN II; Dade Behring, DE). This assay has a sensitivity of less than 0.2 mg/L
with an intra-assay precision (coefficient of variation; CV) of less than 4.4% and an inter-assay
CV of less than 5.7%. Hs-CRP is reported to have long-term stability during storage at −80°
C, a long half-life, negligible diurnal variation, and little covariation with sex.22 In one study,
13 years of storage slightly increased values (although the correlation from baseline to 13-year
levels remained above .90).23 Recommendations for clinical use suggest that a single
assessment is sufficient, except in persons with current acute infections, trauma, or acute
hospitalizations, who may temporarily have hs-CRP levels of 10 mg/L or higher16. Therefore,
participants with highly elevated hs-CRP levels (≥ 10 mg/L) should be excluded from analyses
of cohort data16. IL-6 levels were assessed using a high-sensitivity enzyme-linked
immunosorbent assay kit (Quantikine HS IL-6; R&D Systems, MN) with a sensitivity of 0.156
pg/mL and intra-assay and inter-assay CVs of 3% to 9%. sICAM-1 levels were measured using
a commercially available enzyme-linked immunosorbent assay kit (R&D Systems, MN) with
a sensitivity of 0.35 ng/mL and intra-assay and inter-assay CVs of 3% to 10%.
The diagnostic codes associated with medical care delivered to the survey participants provides
an accurate measure for outcome assessment24 as Nova Scotia provides universal health care
insurance, and events occurring outside Nova Scotia are reimbursed and therefore captured.
Data on occurrences of hospital discharges with a diagnosis code for International
Classification of Disease manual (ICD-9) codes for ischemic heart disease (410.×–414.×, or
the equivalent ICD-10 codes), were gathered from the provincial health care database through
March 31, 2005, the ten-year period following the initial enrollment of participants. To ensure
that all events were incident and not recurrent, all participants were asked about prior CHD
events in the survey and we reviewed discharge diagnoses for each participant for four years
prior to the baseline survey administration; survey respondents with a prior documented/
reported CVD event were excluded. Death status and cause of death, including those who died
in-hospital, at home, or outside of the province, were extracted from the national vital statistics
database for the same ten-year period. For CHD morbidity, a data quality committee from the
Department of Health of Nova Scotia meets regularly with health records personnel to ensure
accuracy and to adjudicate data entry irregularities. For CHD mortality, deaths are coded
provincially and transferred to Statistics Canada, where a national process of determining the
underlying cause of death is applied.
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The primary aim was to test whether statistical adjustment for inflammatory markers reduces
any of the excess CHD incidence risk due to depressive symptoms. The relationship between
baseline depression, inflammation, demographics and cardiac risk factors were tested by simple
and partial correlations. Linear regression was used to quantify the cross-sectional relationship
between depressive symptoms and log-transformed hs-CRP, log-transformed IL-6, and
sICAM-1 biomarker levels5.
The period of follow-up was defined for each participant as starting at the participant’s age at
baseline and extending until either his/her age at first CHD event or age on March 31, 2005
for those who did not have an event during the follow-up period.
Cox proportional hazards models were used to estimate the adjusted hazard ratios of depression
and inflammation for incident CHD. Models were estimated in which depressive symptoms
alone, one inflammatory marker alone, or depressive symptoms and an inflammatory marker
were the primary predictors. We tested the significance of quadratic terms to check for
curvilinearity in the relationships of depressive symptoms and inflammatory measures with
CHD incidence. With CRP and IL-6 log-transformed to reduce severe skewness, there was no
evidence of curvilinearity.
All models were adjusted for sex and age at baseline, the latter to control for cohort and/or
healthy survivor effects, as well as for Framingham risk score, to determine whether depression
and/or inflammation predict CHD over and above traditional cardiovascular risk factors. We
used the Framingham risk score that incorporates the combined effects of seven traditional
cardiovascular risk factors – sex, age, total cholesterol, HDL cholesterol, blood pressure,
history of diabetes, and cigarette smoking – into a single risk score25. Each factor is collapsed
into categories and each category is assigned a score. The scores are then summed to create
the overall risk score. The categorization and assigned scores are defined separately for males
and females. Although the original Framingham Risk Score was not defined for participants
age 75 or older, the scoring algorithm is linear with age for males and quadratic with age for
females and so risk scores could be determined for older participants. For those few participants
who were missing a small number of risk factors, a regression-based approach was used to
impute the expected value of the total Framingham score conditioned on the available risk
factors.
We tested the proportional hazards assumption using the Kolmogorov-type supremumtest26
based on 1,000 simulated replications; this assumption was met (all p>.20).
We conducted secondary analyses to address potential limitations and subgroup differences
suggested in previous studies.7, 27 To examine whether inflammatory markers explain the
relationship between depressive symptoms and CHD differently by subgroup, we tested the
significance of multiplicative interaction terms for sex (male vs female), smoking status
(current vs all others), age (≥65 years vs<65 years), obesity (BMI >30 vs all others),
cardiovascular medication use (aspirin, antihypertensive, or lipid-lowering medication use vs
none), and antidepressant use (yes vs no). All analyses were performed using SAS statistical
software (version 9.1).
Results
Of the 2,305 survey respondents who met the inclusion criteria for this study, data on 1,794
(78%) participants are included in the analysis (see Figure 1). Survey respondents were
excluded due to refusal to permit linkage to medical outcome data, unwillingness or inability
to provide sufficient blood, failure to complete the depression scale, or inability to link
electronic medical outcome data to the study database. Those available for analysis reported
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significantly lower depressive symptom scores than did the excluded group (7.2 vs 8.2;
p=0.02), but there were no other significant demographic differences.
Table 1 shows the baseline characteristics of the 1,794 adults included in our analysis. Table
2 shows the pair-wise correlations for the control variables and for baseline depression and
inflammation, controlling for age, sex, and Framingham risk score. The regression of baseline
log(hs-CRP) and log(IL-6) levels on baseline depressive symptoms, controlling for sex, age,
and Framingham risk score, showed that each standard deviation increase in depressive
symptoms was associated with an 8.3% higher level of hs-CRP and with a 4.7% higher level
of IL-6.
There were 152 (8.5%) incident CHD events (141 nonfatal and 11 fatal events) during the
15,514 person-years (9.8 events/1000 person-years). The hazard rate (HR) estimates from
separate Cox proportional hazards regression analyses (Table 3) show that depressive
symptoms, log(hs-CRP) and sICAM-1 each significantly predict CHD risk. Adjusting for age,
sex and Framingham risk score, each increase of one standard deviation in CES-D scores
increased the rate of incident CHD by 28%. Results were also significant in models predicting
CHD from inflammatory markers; however, IL-6 was not significant after covariate
adjustment.
When both depressive symptoms and log(hs-CRP) levels were included in the same model,
both remained significant and independent predictors, with only minor reduction in their HRs
(Table 4, model 1). When sICAM-1 (model 2) or log(IL-6) (model 3) was added to a model
with CES-D, no meaningful reduction in the estimate for depressive symptoms occurred,
suggesting that inflammation explains little or none of the association between depression and
CHD. In a model that included depressive symptoms, log(hs-CRP) and sICAM-1 (model 4),
each exhibited a statistically significant independent effect on risk of incident CHD, but the
effect of depressive symptoms was attenuated by only 6% after adjusting for the inflammatory
measures. We also repeated model 4, using depressed grouping (score of 10+ vs. 0–9) rather
than the continuous scale, and found the same results (see model 4b). Re-conducting these
analyses with CHD individual risk factors included, rather than the summary Framingham
score, resulted in identical findings—depression’s effect on CHD is not reduced (data not
shown).
Finally, we tested if inflammation might explain the risk for CHD incidence conferred by
depression in subgroups defined by sex, smoking status, age group, obesity, cardiovascular
medication use (aspirin, lipid-lowering, or anti-hypertensive), or antidepressant medication
(models 5–10). We conducted tests of interaction terms to examine whether the association
between depression or inflammation and CHD varied by subgroup and found that depressive
symptoms predict CHD incidence more strongly in smokers (p<0.02) and hs-CRP predicts
CHD incidence more strongly in the non-obese (p<0.02). No other interactions reached
statistical significance.
Discussion
Recent population-based studies have concluded that depression is an independent risk factor
for incident CHD mortality, controlling for established and emerging risk factors28. Thus, the
search for the mechanisms by which depression confers its risk remains urgent, and
inflammation continues to have strong appeal as the most viable candidate11. However, studies
have rarely examined the inter-relations among depression, inflammation, and subsequent
CHD incidence9, particularly in randomly-selected, population-based samples. This study
indicates that depressive symptoms and inflammation are modestly correlated. Further,
depressive symptoms are associated with an increased risk of incident CHD events,
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independent of both traditional risk factors and inflammatory biomarkers, particularly hs-CRP
and sICAM-1 levels. Therefore, inflammatory biomarkers neither fully nor partially explain
the association between depression and CHD incidence.
Our study does not support the long-held theory that inflammation mediates the increased risk
of incident CHD events associated with depression. Our findings are similar to those reported
in a retrospective, nested, case-control study7 of middle-aged European men, in which
depressive symptoms were predictive of a combined endpoint of incident angina pectoris,
nonfatal myocardial infarction, and coronary death, but the increased risk was not reduced by
considering hs-CRP, IL-6, sICAM-1, or fibrinogen levels. Another population-based,
prospective study of apparently healthy European men29 did show that depression status
interacted synergistically with CRP to increase CHD risk, such that those with both depression
and high hs-CRP levels were at substantially higher risk. In our population-based sample, there
was no evidence of such an interaction among men or women. Vaccarino et al13 demonstrated
that depression and inflammation (hs-CRP and IL-6) were independent predictors of nonfatal
myocardial infarction, stroke, congestive heart failure, and cardiovascular death in women
referred for coronary angiogram to evaluate symptoms of chest pain or suspected coronary
ischemia (tests indicated that 16% of the enrolled participants had baseline obstructive CHD).
Finally, recent findings from the Whitehall II study30 suggest that inflammation does not
mediate the relation of negative affect and psychological distress to CHD incidence in a large
cohort of British civil servants. However, this study did not examine depression specifically
nor did it find a relation of negative affect and psychological distress with elevated levels of
inflammation, as measured by hs-CRP, IL-6, and fibrinogen.
Many of these studies did not directly test the independent contributions of depression and
inflammation in relation to the onset of incident CHD events in asymptomatic men and women
from the general population. In contrast, this was a prospective study of a randomly selected,
nationally representative, population-based sample of healthy men and women. The data
collection process made it possible for us to accurately include only people with no diagnosis
of CVD at baseline and to verify CHD status up to ten years after the survey date using
centralized, computerized administrative databases with excellent and independent quality
control of diagnostic codes. Additionally, the random sample collection and the low loss to
follow-up help to minimize concerns of significant selection bias. Depressive symptoms were
modestly, albeit highly significantly, comorbid with inflammation; the association is similar
in size to that found in other large studies7,8. Thus, our findings provide strong evidence that
inflammation does not explain the link between depression and CHD morbidity and mortality.
There are potential limitations to our study. First, we only have measures of depressive
symptoms and inflammation at baseline, so we cannot determine whether the depression
preceded the inflammation, the inflammation preceded the depression or the two developed
simultaneously; nor can we explore mediation in the formal sense recently recommended by
Kraemer and others.31 Future studies with repeated measures during follow-up may help to
reveal the most biologically plausible process by which these risk factors interact. Also, data
on medication use was only available at baseline. It seems likely that some participants began,
stopped and/or switched some of their medications over the ten years of follow up, and we
cannot assess how the duration and changes in medication use impact the associations under
study here. Also, we only examined the use of aspirin, antihypertensive, lipid-lowering, and
antidepressant medications so there may be other potentially relevant medications that were
omitted from our analyses. There was such a low rate of baseline statin medication use (less
than 1% in 1995) so we could not determine if our results would differ for those receiving
statins.
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There are many plausible biological mechanisms suggested to explain why depression is a risk
marker for CHD incidence—dysregulated autonomic function, endothelial dysfunction,
reduced omega-3 fatty acid levels, hyperintensities of white matter (vascular depression),
upregulated platelet aggregation9,32,33—as well as behavioral mechanisms, such as
nonadherence to medication use.34 Despite the evidence that inflammation underlies the
development and progression of CHD, our study strongly suggests that inflammation does not
appear to be a likely mechanism for explaining the link between depression and CHD incidence.
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Table 1
Baseline Characteristics of Population-based, Coronary Heart Disease (CHD)-free, Men and Women Aged 18–
98 Years: Continuous Variables reported as mean ± standard deviation and categorical variables reported as






Age, years 46.3 ± 18.3
Male 895 (49.9%)
Active smoker* 478 (26.6%)
Body mass index (kg/m2) 26.7 ± 5.1
Diabetes mellitus 58 (3.2%)
Center for Epidemiologic Studies- Depression score 7.2 ± 7.7
Center for Epidemiologic Studies- Depression grouping
(10+ vs. 0–9)
477 (26.6%)
Total cholesterol (mmol/L) 5.3 ± 1.1
High density Lipoprotein (mmol/L) 1.3 ± 0.3
Low density Lipoprotein (mmol/L) 3.3 ± 0.9
Systolic blood pressure (mmHg) 124.2 ± 16.6
Diastolic blood pressure (mmHg) 76.5 ± 9.4
Framingham risk score 1.4 ± 9.1
High sensitivity C-reactive protein (mg/L)** 0.17 ± 1.25
Interleukin-6 (pg/mL)** 0.16 ± 0.79
High sensitivity C-reactive protein ≥ 3.0 (mg/L) 465 (26.0%)
Soluble Intercellular Adhesion Molecule-1 (ng/mL) 565.0 ± 329.7
Use of
    Aspirin 73 (4.1%)
    Lipid-lowering medication 23 (1.3%)
    Antihypertensive medication 182 (10.1%)
    Antidepressants 52 (2.9%)
Total sample size=1794.
*
Defined as smoking more than 1 cigarette per day in the past year.
**
log transformed (natural log)
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Table 3
Bivariate Association of Each Covariate, Depressive Symptoms and Inflammatory Markers with 10-year Incident
Coronary Heart Disease or Mortality




Hazard Ratio (95% CI)
Sex of Participant Male (vs Female) 1.58 (1.14–2.18) -
Age Per SD (1 SD = 18.2 yrs) 6.30 (2.22–17.9) -








10+ vs. 0–9 1.55 (1.09–2.20) 1.60 (1.12–2.28)
Log high sensitivity C-
reactive protein





Per SD (1 SD = 330 ng/mL) 1.33 (1.06–1.66) 1.32 (1.05–1.67)
Log Interleukin-6 Per SD (1 SD = 0.79) 1.17 (1.00–1.36) 1.07 (0.90–1.27)
Total sample size =1794.
*
Adjusted for sex, age, and Framingham risk score
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Table 4
Hazard ratios and 95% confidence intervals per 1 standard deviation increase in baseline value of predictor for
incident Coronary Heart Disease morbidity or mortality comparing a model with (Center for Epidemiological
Studies- Depression), adjusted for age, sex, and Framingham risk score (model A) to a model additionally
including inflammatory markers (model B)






















1. 1790 1.27 (1.10–1.47) 1.26 (1.09–1.45) 1.25 (1.02–1.53) 5.68%
2. 1792 1.28 (1.11–1.48) 1.28 (1.11–1.48) 1.32 (1.04–1.66) −0.08%
3. 1751 1.28 (1.10–1.48) 1.27(1.10–1.47) 1.05 (0.88–1.25)° 1.22%





1788 1.60 (1.12–2.27) 1.59 (1.12–2.26) 1.26 (1.03–1.54) 1.29 (1.03–1.63)
0.88%
5. Men 890 1.25 (1.02–1.52) 1.22 (1.00–1.50) 1.23 (0.94–1.61)° 1.10 (0.80–1.51)° 8.45%
6. Current smokers 475 1.49 (1.21–1.83) 1.55 (1.25–1.92) 1.00 (0.68–1.46)° 1.58 (1.04–2.40) −10.77%
7. Age ≥65 years 345 1.23 (0.94–1.61)° 1.20 (0.92–1.58)° 1.23 (0.90–1.66)° 1.70 (1.17–2.48) 11.10%
8. Body













aspirin, lipid-lowering medications and anti-hyerpertensive medications
1 standard deviation of depressive symptoms = 7.7 points;
1 standard deviation of log(high sensitivity C-reactive protein) = 1.25; 1 standard deviation of soluble intracellular adhesion molecule-1 = 330 ng/
mL; 1 standard deviation of log(interleukin-6) = 0.79
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